RAPID 1: A 52-week trial in adult patients with moderately to severely active RA

RAPID 1 study design1,2

Graph representing RAPID 1 study design

RAPID 1 was a 52-week, multicenter, randomized, double-blind, placebo-controlled study in 982 adult patients with active RA for at least 6 months prior to baseline, diagnosed according to the American College of Rheumatology criteria, and with ≥9 swollen and tender joints. Patients were randomized to receive CIMZIA 200 mg (n=393) or 400 mg (n=390) or placebo (n=199) subcutaneously every other week following a loading dose with CIMZIA 400 mg or placebo at weeks 0, 2, and 4. Patients in all 3 study arms also received weekly methotrexate (MTX). The co-primary endpoints were American College of Rheumatology 20% improvement (ACR20) response rate at week 24 and mean change from baseline in modified total Sharp score (mTSS) at week 52.1,2